Characterizing monoclonal antibodies to SARS-CoV-2

Characterizing monoclonal antibodies to SARS-CoV-2
  • Prioritized group of eight original assays that measure non-redundant activities mediated by different effector populations (monocytes/macrophages, neutrophils, NK cells, complement, mucins)
  • Developed two additional assays to measure specific SARS-CoV2 risk factors
    • Antibody-dependent enhancement of infection; risk that mAb might increase uptake of virus if used for prophylaxis
    • Antibody-dependent macrophage activation; risk that mAb might increase severity of disease course if used for treatment

updated: 1 week ago